CY1111467T1 - Μορια ανθρωπινου αντισωματος για την il-13 - Google Patents

Μορια ανθρωπινου αντισωματος για την il-13

Info

Publication number
CY1111467T1
CY1111467T1 CY20111100456T CY111100456T CY1111467T1 CY 1111467 T1 CY1111467 T1 CY 1111467T1 CY 20111100456 T CY20111100456 T CY 20111100456T CY 111100456 T CY111100456 T CY 111100456T CY 1111467 T1 CY1111467 T1 CY 1111467T1
Authority
CY
Cyprus
Prior art keywords
motorcycle
ill
human response
antibody molecules
hodgkin
Prior art date
Application number
CY20111100456T
Other languages
Greek (el)
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of CY1111467T1 publication Critical patent/CY1111467T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100456T 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13 CY1111467T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
EP04743400A EP1646656B1 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (1)

Publication Number Publication Date
CY1111467T1 true CY1111467T1 (el) 2015-08-05

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100456T CY1111467T1 (el) 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13

Country Status (8)

Country Link
JP (3) JP5519567B2 (enrdf_load_stackoverflow)
KR (1) KR101073590B1 (enrdf_load_stackoverflow)
AU (1) AU2011200308B2 (enrdf_load_stackoverflow)
CY (1) CY1111467T1 (enrdf_load_stackoverflow)
HK (1) HK1216427A1 (enrdf_load_stackoverflow)
MX (1) MXPA06000258A (enrdf_load_stackoverflow)
NO (2) NO338853B1 (enrdf_load_stackoverflow)
RU (1) RU2009148270A (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811177SA (en) * 2014-06-18 2019-01-30 Medimmune Llc Cell culture methods and media comprising n-acetylcysteine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508179A (ja) * 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
ES2384100T3 (es) * 2001-12-03 2012-06-29 Alexion Pharmaceuticals, Inc. Método para producir anticuerpos híbridos
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1534323A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
JP5922686B2 (ja) 2016-05-24
KR101073590B1 (ko) 2011-10-14
NO338853B1 (no) 2016-10-24
JP2016047843A (ja) 2016-04-07
AU2011200308A1 (en) 2011-02-17
HK1216427A1 (zh) 2016-11-11
NO342727B1 (no) 2018-07-30
KR20060054312A (ko) 2006-05-22
AU2011200308B2 (en) 2011-07-28
HK1097853A1 (en) 2007-07-06
RU2009148270A (ru) 2011-06-27
NO20160707A1 (no) 2016-04-27
JP2011147454A (ja) 2011-08-04
JP5519567B2 (ja) 2014-06-11
JP2014101372A (ja) 2014-06-05
NO20060730L (no) 2006-04-10
MXPA06000258A (es) 2006-07-03
HK1155185A1 (en) 2012-05-11

Similar Documents

Publication Publication Date Title
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2005007699A8 (en) Human antibody molecules for il-13
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
TNSN08333A1 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
MX2009010765A (es) Anticuerpos anti-ige.
IL182764A0 (en) Methods for treating obesity and obesity related diseases and disorders
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
WO2004090539A3 (en) Methods of determining efficacy of treatments of inflammatory diseases of the bowel
ECSP066297A (es) Anticuerpos contra interleucina 22 y usos de los mismos
CY2014007I1 (el) Μεθοδοι για την αγωγη διαταραχων ή παθησεων που συσχετιζονται με υπερλιπιδαιμια και υπερχοληστερολαιμια ενω ελαχιστοποιουνται οι παρενεργειες
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
DK2262778T3 (da) 1-benzyl-3-hydroxymethylindazolderivativer og brug deraf i behandling af sygdomme baseret på ekspression af mcp-1, cxcr1 og p40
DK1593387T3 (da) Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser
BRPI0413418A (pt) aptámero, e, composição farmacêutica
CY1111467T1 (el) Μορια ανθρωπινου αντισωματος για την il-13
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
WO2006048781A3 (en) IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
Khaniyan et al. Understanding exercise behavior among Tehran adolescent girls according
Habibi et al. Effectiveness of dialectical behavior therapy in improving symptoms of patients with dysthymic disorder
TH101957A (th) แอนตี้บอดี้ต่อ il-13 ของมนุษย์และการใช้ทางอายุรเวช